Applied Genetic Technologies : AGTC Corporate Presentation

This presentation contains forward-looking statements that reflect Applied Genetic Technologies Corporation's ("AGTC" or the "Company") plans, estimates, assumptions and beliefs. Forward-looking statements include statements regarding AGTC's proposed Phase 2/3 trial design for XLRP and the proposed Phase 1/2 expansion trial for XLRP, including the effectiveness of

AGTC's pre-selection methodology for pre-specifying loci, its anticipated timeline and potential to receive FDA approval to begin the XLRP pivotal trial, the timing for completing and reporting data in its XLRP and ACHM clinical programs, its ability to enroll patients for its clinical trials, the expected costs of its clinical programs and its planned manufacturing activities, business strategies and operations, regulatory progress, potential growth and market opportunities, and the effects of competition. Forward- looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors. Risks and uncertainties that may cause actual results to differ materially include, among others: AGTC cannot predict when or if it will obtain regulatory approval to continue to progress

its clinical trials, commercialize a product candidate or receive reasonable reimbursement; uncertainty inherent in clinical trials and the regulatory review process; risks and uncertainties associated with drug development and commercialization; risks related to the COVID-19 outbreak that may delay clinical trial enrollment; gene therapy is still novel with only a few approved treatments so far; factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent periodic reports filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this presentation. Except as required by law, AGTC assumes no obligation to update or revise these forward-looking statements publicly, whether as a result of new information, new events or otherwise.

Science

Differentiated With

Demonstrated

Capabilities

Broad pre-clinical data

Robust use of disease- specific animal modeling

Manufacturing XLRP

Unmatched	Potential Best-in-Class
Productivity,	Late-Stage
Scalability & Quality	Asset
10-fold reduction in	Improvements in visual
process residuals and	function sustained for at
10-fold increase in	least six months
productivity	No product related
At commercial scale: 40 L	SAEs across 100-fold
≥ 2000 ophthalmic doses	dose range

Diversified

Pipeline

High-Value

Programs

1Q 21 ACHM data

shows visual sensitivity improvements support continued clinical development

Diversified programs across ophthalmology, neurodegenerative and otology indications

	IND ENABLING	PHASE 1/2	PHASE 2/3	NEXT MILESTONE*	KEY CAPABILITY
OCULAR
XLRP	RPGR (ORPHAN DRUG)			3-month data Skyline 4Q 21
		6-month data Vista 3Q 22
ACHM	CNGB3 (ORPHAN DRUG)			12-month Adult data both trials 2Q 21
			3-month Pediatric data both trials 4Q 21
	CNGA3 (ORPHAN DRUG)
Retinitis Pigmentosa	UNIQUE CHR & NEUROPROSTHETIC		Partnership with Bionic Sight; complete dosing
Dry AMD	COMPLEMENT FACTOR H		IND filing
Stargardts	ABCA4			IND filing
NEURODEGENERATIVE
FTD	PROGRANULIN			IND filing; partnering effort
ALS	C9ORF72			Development candidate; partnering effort
OTOLOGY

	Non-Syndromic	GJB2	Partnership with Otonomy; IND filing
	Hearing Loss
	*Anticipated milestones based on calendar year, not AGTC's fiscal year